Related Experiment Video
Updated: Jul 10, 2026

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies
Published on: May 6, 2022
Homocysteine-mediated PPARalpha,gamma DNA methylation and its potential pathogenic mechanism in monocytes
Jiang Yideng1, Liu Zhihong, Xiong Jiantuan
1Department of Pathophysiology, Ningxia Medical College, Yinchuan, Ningxia, PR China. jwcjyd@163.com
Insights
High homocysteine (Hcy) levels increase DNA methylation of PPARalpha,gamma in monocytes, potentially driving atherosclerosis. This epigenetic change offers a new therapeutic target for cardiovascular disease prevention.
Area of Science:
- Molecular Biology
- Epigenetics
- Cardiovascular Research
Background:
- Homocysteine (Hcy) is a known risk factor for cardiovascular disease.
- The molecular mechanisms linking Hcy to atherosclerosis in monocytes are not fully understood.
Purpose of the Study:
- To investigate the impact of Hcy on DNA methylation of Peroxisome proliferator-activated receptors alpha and gamma (PPARalpha,gamma) in monocytes.
- To elucidate the mechanism by which Hcy influences PPARalpha,gamma expression.
Main Methods:
- Monocytes were cultured with varying concentrations of Hcy (50-500 microM).
- PPARalpha,gamma expression (mRNA and protein) was measured using real-time RT-PCR and Western blotting.
- DNA methylation levels of PPARalpha,gamma promoter were quantified using a high-throughput methylation assay.
- Levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were analyzed via HPLC.
Main Results:
- Hcy exposure increased PPARalpha,gamma promoter methylation in monocytes, with peak effects at 100 microM Hcy.
- Hcy significantly decreased both mRNA and protein levels of PPARalpha,gamma.
- Hcy elevated SAH levels, reduced SAM levels and the SAM/SAH ratio, and increased C-5MT-ase activity.
Conclusions:
- Hcy-induced DNA methylation of PPARalpha,gamma in monocytes is a potential mechanism contributing to atherosclerosis.
- These findings suggest that targeting Hcy-induced epigenetic modifications of PPARalpha,gamma could be a therapeutic strategy for preventing Hcy-related atherosclerosis.
Abstract:
Homocysteine (Hcy) is an independent risk factor for cardiovascular disease, but the molecular mechanisms causing atherosclerosis in monocytes remain poorly characterized. The objective of the present study was to investigate the effects of Hcy on DNA methylation of PPARalpha,gamma and the underlying mechanism of PPARalpha,gamma expression that was induced by Hcy in monocytes. About 50, 100, 200, and 500 microM Hcy were added to the monocytes cultured for 48 h. PPARalpha,gamma that acted as lipid sensors and bind with mM affinities to ligands of antiatherosclerosis were determined by real-time reverse transcription-polymerase chain reaction and Western blotting in monocytes. Here, we used a high-throughput quantitative methylation assay that utilizes fluorescence-based real-time polymerase chain reaction to determine the levels of the PPARalpha,gamma DNA methylation. S-adenosylmethionine (SAM) level and S-adenosylhomocysteine (SAH) level were detected by high performance liquid chromatography. Results indicated that the levels of PPARalpha,gamma promoter methylation in monocytes cultured with Hcy were increased in comparison with the control group, and the peak was in the 100 muM Hcy group, however, a dose-dependent increase with increasing Hcy was not seen. Hcy also decreased mRNA and protein levels of PPARalpha,gamma in monocytes. Further, with the addition of Hcy, the levels of SAH were elevated, the levels of SAM and the ratio of SAM/SAH were lower, and the activity of C-5MT-ase was increased. In conclusion, these results suggest that PPARalpha,gamma DNA methylation induced by Hcy may represent an important mechanism to explain atherosclerosis, which may become a therapeutic target for preventing atherosclerosis induced by Hcy.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Master Transcription Regulators
